4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Amblyopia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 3 ongoing clinical trials involving Amblyopia
Of the 3 trials,2 trials are in Phase II
Furthermore, 1 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Amblyopia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Amblyopia, an ophthalmology indication. Europe, and Asia-Pacific are the regions involved in Amblyopia-related drug trials.

Amblyopia related clinical trial sponsors

SooChow University, Jiangsu Province People's Hospital, and Moorfields Eye Hospital NHS Foundation Trust are a few notable sponsors involving Amblyopia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Atrial Fibrillation

Atropine sulfate (Atropine sulfate), Atropine (Atropine), Atropine sulphate, prednisolone and chlorobutanol (Atrisolon) are among the key marketed drugs involving Atrial Fibrillation.

Atropine sulfate is a tropane alkaloid, acts as an antimuscarinic agent. It functions via Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Antagonist mechanism of action. It is formulated as solution for drops for ophthalmic route of administration. Atropine is used for the treatment of Amblyopia, Cycloplegia, and Mydriasis. Atropine was first approved in 2021 and is marketed globally including the US, by Apotex Corp.

Atropine is an alkaloid derivative from atropa belladonna acts as a cycloplegic and mydriatic and anti-cholinergic agent. It functions via Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Antagonist mechanism of action. It is formulated as drops for ophthalmic route of administration. Atropine is marketed for the treatment of Amblyopia, Cycloplegia, and Mydriasis. It is marketed in India by Flagship Biotech International Pvt Ltd.